 Pharmaceutical composition containing an HDAC inhibitor and a cyclopolysaccharide
专利摘要:
公开号:ES2662775T9 申请号:ES12831417T 申请日:2012-09-14 公开日:2019-05-16 发明作者:Yu Chen；Lan Yang；Feiyu Feng；Qiufu Ge；Dianwu Guo；Yi Chen 申请人:Euro Celtique SA； IPC主号:
专利说明:
[0001] [0002] Pharmaceutical composition containing an HDAC inhibitor and a cyclopolysaccharide [0003] [0004] Related requests [0005] [0006] The present application is an international application that claims the priority and benefit of the US provisional application. No. 61 / 536,038, filed on September 18, 2011 and provisional application of the United States No. 61 / 602,408, filed on February 23, 2012. [0007] [0008] Background [0009] [0010] Cancer is one of the most life-threatening diseases in which the cells in one part of the body experience out-of-control growth. According to the latest data from the American Cancer Society, there are an estimated 1.6 million new cancers in the United States in 2011. Cancer is the second leading cause of death in the United States (second only after of cardiac disease) and claim more than 570,000 lives in 2011. In fact, it is estimated that 50% of all men and 33% of all women living in the United States will develop some type of cancer in their lifetime. Thus, cancer constitutes a significant burden of public health and represents a significant cost in the United States. For decades, surgery, chemotherapy and radiation were well-established treatments for various cancers. Patients usually receive a combination of these treatments according to the type and extent of their disease. But chemotherapy is the most important option for the patient with cancer when surgical treatment is impossible. [0011] Bendamustine, a well-known chemotherapy first synthesized in 1963, consists of an alkylating nitrogen mustard moiety and a purine-type benzimidazole moiety with a suggested purine-analogous effect (Barman Balfour JA, et al., Drugs 2001; 61 : 631-640). Bendamustine showed substantial activity against low grade lymphomas (Herold M, et al., Blood, 1999; 94, Suppl 1: 262a), multiple myelomas (Poenisch W, et al., Blood 2000; 96, Suppl 1: 759a) and several solid tumors (Kollmannsberger C, et al., Anticancer Drugs 2000; 11: 535-539). It was also reported that bendamustine effectively induces apoptosis in lymphoma cells (Chow KUT, et al., Haematologica, 2001; 86: 485-493). In March 2008, the FDA granted approval to launch bendamustine for the treatment of chronic lymphocytic leukemia (CLL). In October 2008, the FDA also granted approval to market bendamustine for the treatment of indolent B-cell non-Hodgkin lymphoma (NHL) that progresses during or within six months of treatment with rituximab or a regimen containing rituximab. . [0012] [0013] The clinical activity of bendamustine as the only agent and in combination with other chemotherapeutic and immunotherapeutic drugs, coupled with its potential lack of cross-resistance with many other chemotherapeutic agents, make bendamustine an attractive therapy for patients with newly diagnosed and refractory hematological malignancies [Leoni LM, Semin Hematol. 2011 Apr; 48 Suppl 1: S4-11]. Currently, bendamustine has approximately 75 active clinical assays for a variety of cancer indications, such as leukemia, lymphoma, small cell lung cancer, multiple myeloma, MDS, ovarian cancer, breast cancer and brain tumor. Bendamustine, marketed by Cefalon (TREANDA ™), has annual sales of 393 million dollars in the United States in 2010 and sales of more than 500 million dollars in the United States in 2011. Peak sales in 2015 can reach one billion dollars. The exclusive marketing right of bendamustine in the United States will expire in 2015. [0014] [0015] Although bendamustine made a significant contribution to the treatment of cancer, dose-limiting toxicities and drug resistance remain significant obstacles in its use. [0016] [0017] In recent years, histone deacetylase (HDAC) has emerged as an important target of the disease for the treatment of cancer [Minucci, S. et al., Nat Rev Cancer 2006, 6, 38-51]. Human HDAC enzymes have 18 isoforms grouped in class I-IV according to their sequence homology. Classes I, II and IV, commonly referred to as classic HDACs, are made up of 11 family members. The HDACs of class III consist of 7 enzymes and are different from other members of the HDAC family, therefore, they are given an exclusive term of sirtuins. The inhibition of the HDAC enzyme leads to the acetylation of histone that is associated with chromatin remodeling and plays a key role in the epigenetic regulation of the gene expression. In addition, HDAc inhibitors were shown to evoke the acetylation of many non-histone important proteins such as HSP90, alpha-tubulin, Ku-70, Bcl-6, importin, cortactin, p53, STAT1, E2F1, GATA-1 and NF-kB, that can disrupt many important signaling networks related to the treatment of cancer. The underlying mechanism of action of HDAC inhibitors includes differentiation, arrest of the cell cycle, inhibition of DNA repair, induction of apoptosis, up-regulation of tumor suppressors, down-regulation of factors of growth, oxidative stress and autophagy. In the last decade, a large number of structurally diverse HDAC inhibitors have been identified and at least 12 HDAC inhibitors are currently in human clinical trials for cancer treatments, including short chain fatty acid (valproic acid), hydroxamates (SAHA, LBH589, PXD101, JNJ-26481585, ITF2357, CUDC-101), cyclic tetrapeptides (FK-228), benzamide (MS-275) and various other compounds (CHR-3996, 4SC-201, SB939). Among them, SA hA and FK-228 were approved by the US FDA for the treatment of advanced cutaneous T-cell lymphoma. [0018] In WO / 2010/085377, we report NL-101, a bendamustine derivative of dual functionality first in the class that potentially inhibits the HDAC pathway. The structure of the parent drug bendamustine and NL-101 is shown below: [0019] [0020] [0021] [0022] [0023] The biological assay showed that NL-101 potentially inhibits the HDAC enzyme (HDAC1 IC 50 of 9 nM). NL-101 was sent to NCI (NSC # 751447) for the control of the NCI-60 cell line panel. The data showed that NL-101 is approximately 25-100 times more potent than bendamustine in NCI-60 cell lines that are representative of a variety of human cancer types. The 60 GI 50 values (one for each cell line) make up the footprint of NL-101 and based on this footprint, the COMPARE analysis was performed using the COMPARE algorithm on the NCI DTP website. A Pearson correlation coefficient (PCC) of> 0.8 indicates> 65% agreement on the sensitivity patterns of two compounds and a high probability of a common mechanism of action. The result of COMPARE showed that the NL-101 trace does not correlate strongly with any of the synthetic NSC compounds (> 140,000). In fact, the upper matching compound is epidoxoform (a derivative of doxorubicin) with a PCC of 0.676. Direct comparisons between NL-101 and conventional nitrogen mustard (for example, bendamustine, melphalan and chlorambucil) showed weak correlation coefficients (PCC <0.483). These COMPARE results suggested that NL-101 is not just another conventional nitrogen mustard but has unique mechanical characteristics that differentiate it from conventional DNA alkylating agents. In other words, NL-101 is expected to have no cross-resistance to conventional DNA alkylating agents. Thus, NL-101 could have broad potential applications for cancer patients who are resistant, relapsing or refractory to conventional DNA alkylating agents such as bendamustine, melphalan, cisplatin and temozolomide. [0024] [0025] We have developed a first-generation formulation of NL-101 for the in vivo study, which contains 6 mg / ml of NL-101 in buffer system (1.5% acetic acid / 0.2% NaOH) with a value of Approximately pH 4. The animal study using the first-generation formulation of NL-101 shows excellent in vivo efficacy in animal models such as imatinib-resistant Philadelphia positive chromosome-positive lymphoblastic leukemia (Ph + ALL) and lung cancer. Ph + ALL is a common leukemia in adults (~ 35% ALL in adults) and carries a poor prognosis. Vincristine (VCR), doxorubicin (Dox), cytarabine (AraC) and cyclophosphamide (CTX) are conventional chemotherapy for the treatment of Ph + ALL. Our data showed that a single dose of NL-101 (60 mpk) has significantly better in vivo efficacy than bendamustine, SAHA, VCR, Dox, AraC and CTX (each dosed to MTD) in the Ph + ALL model resistant to imatinib. The weekly dose of NL-101 at 60 mg / kg is similar in efficacy to Sprycel, which is a second-line drug approved by the FDA for the treatment of Ph + ALL. However, the first-generation formulation of NL-101 unfortunately has significant disadvantages, such as low pH value, potential precipitation after injection, and series of side effects (eg, tail of damaged mice after iv injection and sometimes sudden death of the mice after rapid iv injection due to cardiotoxicity). Therefore, there is a strong need to develop a new generation formulation NL-101 that can overcome the failures of the first generation formulation, in particular cardiotoxicity and can be used in future human clinical trials. [0026] [0027] Compendium of the invention [0028] [0029] The present invention relates to a composition comprising (a) a cyclopolysaccharide and (b) a compound of the formula (II) [0030] [0031] [0032] wherein Ri and R 2 are, independently, H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halo, -C = NH, amine, cyano, hydroxy or alkoxy or one of their pharmaceutically acceptable salts: wherein m is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 0 16; [0033] [0034] and X 1 is halo or OSO 2 Rc, wherein Rc is alkyl, alkenyl or alkynyl. [0035] [0036] The most preferred compound of the above described compound is represented by the formula (III) (ie NL-101): [0037] [0038] [0039] [0040] [0041] In another aspect, a preferred pharmaceutically acceptable salt is a hydrochloride salt, hydrobromide salt, methanesulfonate, toluenesulfonate, acetate, fumarate, sulfate, bisulfate, succinate, citrate, phosphate, maleate, nitrate, tartrate, benzoate, bicarbonate, carbonate, salt of sodium hydroxide, calcium hydroxide salt, potassium hydroxide salt, tromethamine salt or mixtures thereof. A more preferred pharmaceutically acceptable salt is a salt of hydrochloride, methanesulfonate, toluenesulfonate, acetate, succinate, citrate, maleate, tartrate or mixtures thereof. The most preferred pharmaceutically acceptable salt of all is an acetate salt. [0042] [0043] In another aspect, a preferred cyclodextride is a-cyclodextrin or one of its derivatives, p-cyclodextrin or one of its derivatives and Y-cyclodextrin or one of its derivatives. A more preferred cyclopolysaccharide is p-cyclodextrin or one of its derivatives. The most preferred cyclopolysaccharide is hydroxypropyl p-cyclodextrin or sulfobutylether p-cyclodextrin. [0044] [0045] As shown below in Example 6, we were surprised to find that the composition comprising NL-101 and hydroxypropyl p-cyclodextrin can significantly reduce cardiotoxicity in vivo. On the other hand, as shown below in Example 10, in an NSCLC xenograft model A549, animals treated with a composition comprising NL-101 and hydroxypropyl p-cyclodextrin showed significantly less tumor size compared to animals treated with the main drug bendamustine and the vehicle group. [0046] [0047] The compositions of the present invention are useful in the treatment of a patient who has a tumor. The compounds of the invention may also be useful in the prevention and treatment of an immune disease. [0048] This invention also relates to a composition for treating a neoplastic disorder (eg, cancer, myelodysplastic syndrome or myeloproliferative disease) by administration to a subject in need thereof of an effective amount of compositions described above. [0049] [0050] On the other hand, this invention relates to a composition for treating an immune disease (e.g., rheumatoid arthritis and multiple sclerosis) by administration to a subject in need thereof of an effective amount of their compositions described above. [0051] [0052] The details of one or more embodiments of the invention are set forth in the following description. Other features, objects and advantages of the invention will be obvious from the description and from the claims. [0053] [0054] Detailed description [0055] [0056] In a first embodiment, the invention is a composition comprising (a) cyclopolysaccharide, and (b) a compound of formula (II) illustrated above or its enantiomers, diastereomers, racemates, pharmaceutically acceptable salts and solvates thereof. [0057] [0058] In a most preferred embodiment, the invention is a composition comprising (a) cyclopolysaccharide and (b) a compound of the formula (III) illustrated above or its enantiomers, diastereomers, racemates, pharmaceutically acceptable salts and solvates thereof. [0059] The example compounds described herein include the following: [0060] [0061] [0062] [0063] [0064] Accordingly, the compounds can exist as diastereomers, enantiomers or mixtures thereof. Synthesis of the compounds can employ racemates, diastereomers or enantiomers as starting materials or as intermediates. The diastereomeric compounds can be separated by chromatographic methods or crystallization. Similarly, enantiomeric mixtures can be separated using the same or other techniques known in the art. Each of the asymmetric carbon atoms may be in the R or S configuration and both configurations are within the scope of the invention. [0065] [0066] It should be recognized that the compounds of the present invention may be present and optionally administered in the form of salts or solvates. [0067] [0068] For example, it is within the scope of the present invention to convert the compounds of the present invention and use them in the form of their pharmaceutically acceptable salts derived from various organic and inorganic acids and bases according to procedures well known in the art. [0069] [0070] When the compounds of the present invention possess a free base form, the compounds can be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, for example, halohydrates such as hydrochloride, hydrobromide, iodohydrate; other mineral acids such as sulfate, nitrate, phosphate, etc .; and alkyl- and monoarylsulfonates such as ethanesulfonate, toluenesulfonate and benzenesulfonate; and other organic acids and their corresponding salts such as acetate, tartrate, maleate, succinate, citrate, benzoate, salicylate and ascorbate. Other salts by addition of acid of the present invention include, without limitation: adipate, alginate, arginate, aspartate, bisulfate, bisulfite, bromide, butyrate, camphorrate, camphorsulfonate, caprylate, chloride, chlorobenzoate, cyclopentanepropionate, digluconate, dihydrogen phosphate, dinitrobenzoate , dodecyl sulfate, fumarate, galacteriate (of mucic acid), galacturonate, glucoheptonate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hipurate, hydrochloride, hydrobromide, iodide, 2-hydroxyethane sulfonate, iodide, isothionate, isobutyrate, lactate, lactobionate, malate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, monohydrogen phosphate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, pamoate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate and phthalate. It should be recognized that the free base forms generally differ in part from their respective salt forms in physical properties such as solubility in polar solvents, but in other respects the salts are equivalent to their respective free base forms for the purposes of this invention. [0071] When the compounds of the present invention possess a free acid form, a salt can be prepared by adding pharmaceutically acceptable base by reacting the free acid form of the compound with a pharmaceutically acceptable inorganic or organic base. Examples of such bases are alkali metal hydroxides which include potassium, sodium and lithium hydroxides; alkaline earth metal hydroxides such as barium and calcium hydroxides; alkali metal alkoxides, for example, potassium ethanolate and sodium propanolate; and various organic bases such as ammonium hydroxide, piperidine, diethanolamine and N-methylglutamine. Aluminum salts of the compounds of the present invention are also included. Other base salts of the present invention include, without limitation: copper, ferrite, ferrous, lithium, magnesium, manganese, manganese, potassium, sodium and zinc salts. Salts of organic bases include, without limitation, salts of primary, secondary and tertiary amines, substituted amines including natural substituted amines, basic amines and basic ion exchange resins, eg, arginine, betama, caffeine, chloroprocama, choline, N, N'-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethanolamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lidocame, lysine, meglumine, N-methyl-D-glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethanolamine, triethylamine, trimethylamine, tripropylamine and tris- (hydroxymethyl) -methylamine (tromethamine). It should be recognized that the forms of free acids generally differ in part from their respective salt forms in physical properties such as solubility in polar solvents, but in other respects the salts are equivalent to their respective forms of free acids for the purposes of the present invention. . [0072] [0073] The compounds of the present invention comprising groups containing basic nitrogen can be quaternized with those agents such as (C 1-4 ) alkyl halides, for example, methyl, ethyl, iso-propyl and tert-butyl chlorides, bromides and iodides. ; di (C 1-4 ) alkyl sulfates, for example, dimethyl, diethyl and diamyl sulfates; alkyl halides, for example, decyl, dodecyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; and (C 1-4 ) alkyl halides, for example, benzyl chloride and phenethyl bromide. These salts allow the preparation of both water-soluble and oil-soluble compounds of the present invention. [0074] [0075] The compounds of the present invention comprising a tertiary nitrogen atom can be oxidized by those agents such as hydrogen peroxide (H 2 O 2 ), Caro acid or peracids such as meta-chloroperoxybenzoic acid (mCPBA) to form amine oxide. The amine oxides of anticancer agents have been developed as prodrugs and may be soluble in water. [0076] [0077] Cyclopolysaccharides: Cyclopolysaccharides that can be employed in the practice of this invention include cyclodextrins, cyclomannines, cycloaltrins, cyclophrucins, and the like. In general, cyclopolysaccharides comprising between 6 and 8 sugar units are preferred. Among the preferred cyclopolysaccharides that can be used are cyclodextrins. [0078] [0079] Cyclodextrins are cyclic dextrose oligomers with a truncated cone structure consisting of a hydrolytic outer cavity and a hydrophobic inner cavity. A cyclodextrin can form an inclusion complex with a host molecule by complexation with all or a portion of a hydrophobic host molecule within its cavity. The size of the cavity is determined by the number of glucopyranose units in the cyclodextrin. Alpha- (a), beta- (p) and gamma- (Y) cyclodextrins are the most common cyclodextrins and possess six, seven and eight glucopyranose units, respectively. As natural cyclodextrins have a relatively low aqueous solubility and are associated with toxicity, the chemically modified derivatives of cyclodextrin were developed to overcome these limitations. These cyclodextrin derivatives normally have a chemical modification in one or more of the 2, 3 or 6 positions of the hydroxyl groups. Cyclodextrin derivatives have been described, for example, in U.S. Patents Nos. 5,134,127, 5,376,645, 5,571,534, 5,874,418, 6,046,177 and 6,133,248. [0080] [0081] As used herein, the terms "cyclodextrin", "α-cyclodextrin", "p-cyclodextrin and" Y-cyclodextrin "are intended to comprise unmodified cyclodextrins, as well as their chemically modified derivatives. The compositions of the invention comprise an inclusion complex of an α-cyclodextrin and a compound of the formulas (II) or (III). [0082] In yet another embodiment, the composition comprises a therapeutically effective concentration of a compound of formulas (II) or (III). [0083] [0084] In one embodiment of the invention, the composition comprises a cyclodextrin selected from the group consisting of a-cyclodextrin, p-cyclodextrin and Y-cyclodextrin. [0085] [0086] In another embodiment, the cyclodextrin is a p-cyclodextrin and Y-cyclodextrin. [0087] [0088] In a further embodiment, the cyclodextrin is a p-cyclodextrin. [0089] [0090] In another embodiment, the cyclodextrin is selected from the group consisting of a hydroxypropyl-p-cyclodextrin (Pitha et al., J Pharm Sci, 84 (8), 927-32 (1995)) and p-cyclodextrin derived with sulfobutyl (described , for example, in U.S. Patent Nos. 5,134,127, 5,376,645, 5,874,418, 6,046,177 and 6,133,248). [0091] [0092] In another embodiment, the cyclodextrin is a hydroxypropyl p-cyclodextrin. [0093] [0094] In yet another embodiment of the invention, the cyclodextrin is sulfobutylether-p-cyclodextrin. [0095] [0096] Other preferred cyclopolysaccharides include, but are not limited to, p-cyclodextrin substituted with 2-hydroxy-N, N, N-trimethylpropanammonium, carboxymethylated p-cyclodextrin, O-phosphated p-cyclodextrin, succinyl- (2-hydroxy) propyl-beta-cyclodextrin, p -sulfopropylated cyclodextrin, heptakis (6-amino-6-deoxy) -p-cyclodextrin, O-sulphated p-cyclodextrin and 6-monodeoxy-6-mono (3-hydroxy) propylamino-p-cyclodextrin. [0097] [0098] The cyclodextrin may be included in an amount that increases the solubility of the active compound in the composition. In one embodiment, the amount of cyclodextrin included within the composition is the minimum amount necessary to solubilize the drug in the composition. In another embodiment, the composition is a parenteral formulation and the amount of cyclodextrin included within the formulation is the minimum amount of cyclodextrin necessary to solubilize the drug. [0099] [0100] In order to determine the minimum amount of cyclodextrin necessary to solubilize a compound comprised by the II-NI formulas, a graph of the solubility of the compound versus the concentration of the cyclodextrin can be carried out. By interpolating or extrapolating from the graph, a composition containing the minimum amount of cyclodextrin necessary to dissolve the desired concentration of the active compound can be prepared. [0101] [0102] In one embodiment, the composition comprises at least 2.5% (weight / volume) of a cyclodextrin. In another embodiment, the composition comprises at least 5% of a cyclodextrin. In yet another embodiment, the composition comprises at least 10% of a cyclodextrin. In another embodiment, the composition comprises from 2.5 to 40% of a cyclodextrin. In yet another embodiment, the composition comprises from 5% to 20% of a cyclodextrin. In another embodiment, the composition comprises from 7.5% to 15% of a cyclodextrin. In still another embodiment, the composition comprises about 10% of a cyclodextrin. [0103] [0104] In one embodiment, the composition comprises at least 2.5% (weight / volume) of a p-cyclodextrin. In another embodiment, the composition comprises at least 5% of a p-cyclodextrin. In yet another embodiment, the composition comprises at least 10% of a p-cyclodextrin. In another embodiment, the composition comprises from 2.5 to 40% of a p-cyclodextrin. In yet another embodiment, the composition comprises from 5% to 20% of a p-cyclodextrin. In another embodiment, the composition comprises from 7.5% to 15% of a p-cyclodextrin. In yet another embodiment, the composition comprises 10% of a p-cyclodextrin. [0105] [0106] In one embodiment, the composition comprises at least 2.5% (weight / volume) of a hydroxypropyl p-cyclodextrin or sulfobutylether p-cyclodextrin. In another embodiment, the composition comprises at least 5% of a hydroxypropyl p-cyclodextrin or sulfobutylether p-cyclodextrin. In yet another embodiment, the composition comprises at least 10% of a hydroxypropyl p-cyclodextrin or sulfobutylether p-cyclodextrin. In another embodiment, the composition comprises from 2.5 to 40% of a hydroxypropyl p-cyclodextrin or sulfobutylether p-cyclodextrin. In yet another embodiment, the composition comprises from 5% to 20% of a hydroxypropyl p-cyclodextrin or sulfobutylether p-cyclodextrin. In another embodiment, the composition comprises from 7.5% to 15% of a hydroxypropyl p-cyclodextrin or sulfobutylether p-cyclodextrin. In yet another embodiment, the composition comprises 10% of a hydroxypropyl p-cyclodextrin or sulfobutylether p-cyclodextrin. [0107] In one embodiment, the composition also comprises pH adjusting agents. In another embodiment, the pH adjusting agents are one or more acids, bases or salts. Examples of the acids that can be included in the composition include inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid or mixtures thereof and organic acids such as citric acid, L (-) - malic acid and L (+) acid. tartaric or mixtures of them. Examples of bases that can be included in the composition include sodium hydroxide, potassium hydroxide, calcium hydroxide, tromethamine or mixtures thereof. Examples of the salt that can be included in the composition include sodium bicarbonate, sodium carbonate, sodium citrate or mixtures thereof. In another embodiment, the composition comprising one or more pH adjusting agents has a pH range of 6.0-9.0, preferably 7.0-8.0. [0108] Another embodiment of the invention is a pharmaceutical dosage form that includes a pharmaceutical composition containing 5 to about 500 mg of compound of formula (II), or of formula (III). [0109] In another embodiment, the composition comprises dextran. In yet another embodiment, the composition comprises dextran in an amount ranging from about 1% to about 5% weight / volume of dextran. In another embodiment, the composition comprises from about 2 to about 4% weight / volume of dextran. [0110] [0111] Any inert excipient that is commonly used as a carrier or diluent can be used in compositions of the present invention, such as sugars, polyalcohols, soluble polymers, salts and lipids. The sugars and polyalcohols that may be employed include, without limitation, lactose, sucrose, mannitol and sorbitol. Illustrative of the soluble polymers that can be employed are polyoxyethylene, poloxamers, polyvinylpyrrolidone and dextran. Useful salts include, without limitation, sodium chloride, magnesium chloride and calcium chloride. The lipids that may be employed include fatty acids, fatty acid esters of glycerol, glycolipids and phospholipids. [0112] [0113] In addition, the compositions may also comprise binders (eg, acacia, corn starch, gelatin, carbomer, ethylcellulose, guar gum, hydroxypropylcellulose, hydroxypropylmethylcellulose, povidone), disintegrating agents (eg, corn starch, potato starch, algic acid). , silicon dioxide, croscarmellose sodium, crospovidone, guar gum, sodium starch glycolate, Primogel), buffers (for example, tris-HCL, acetate, phosphate) of different pH and ionic strength, additives such as albumin or gelatin to avoid surface absorption, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts), protease inhibitors, surfactants (e.g., sodium lauryl sulfate), permeation enhancers, solubilizing agents (e.g., glycerol, polyethylene glycerol, cyclodextrins), a glidant (e.g., colloidal silicon dioxide), antioxidants (e.g., ascorbic acid, sodium metabisulfite, butylated hydroxyanisole), (for example, hydroxypropylcellulose, hydroxypropylmethylcellulose), viscosity-improving agents (for example, carbomer, colloidal silicon dioxide, ethylcellulose, guar gum), sweeteners (for example, sucrose, aspartame, dicarboxylic acid), flavoring agents (e.g. , menra, methyl salicylate or orange flavoring), preservatives (eg, thimerosal, blessed alcohol, parabens), lubricants (eg, stearic acid, magnesium stearate, polyethylene glycol, sodium lauryl sulfate), flow assistants (eg, colloidal silicon dioxide), plasticizers (e.g., diethyl phthalate, triethyl citrate), emulsifiers (e.g., carbomer, hydroxypropylcellulose, sodium lauryl sulfate), polymer coatings (e.g., poloxamers or poloxamines), coating and forming agents film (for example, ethyl cellulose, acrylates, polymethacrylates) and / or adjuvants. [0114] [0115] In one embodiment, the compositions are prepared with carriers that will protect from rapid elimination of the organism, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene-vinyl acetate, polyanddrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid. Methods for the preparation of such formulations will be obvious to those skilled in the art. The materials can also be obtained in shops of Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes directed to cells infected with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. They can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811. [0116] [0117] The composition of the invention can be reprocessed by mixing a cyclopolysaccharide solution with a mother solution of a compound of the formula (II). This resulting mixture is mixed vigorously and optionally subjected to the action of ultrasonic waves to obtain a homogeneous and balanced aqueous solution. Preferably, the final composition is filtered before use for injection. The composition can optionally be lyophilized to produce a solid material suitable for dissolution in an injection medium before use. [0118] Definitions [0119] [0120] "Acyl" means a carbonyl-containing substituent represented by the formula -C (O) -R, wherein R is H, alkyl, a carbocycle, a heterocycle, alkyl substituted with carbocycle or alkyl substituted with heterocycle, wherein the alkyl, alkoxy, carbocycle and heterocycle are as defined herein. Acyl groups include alkane (for example, acetyl), aroMo (for example, benzoflo), and heteroaroflo. [0121] [0122] "Aliphatic" means a moiety characterized by a straight or branched chain arrangement of constituent carbon atoms and may be saturated or partially unsaturated with one or more double or triple bonds. [0123] [0124] The term "alkyl" refers to a linear or branched hydrocarbon containing 1-20 carbon atoms (eg, C 1 -C 10 ). Examples of alkyl include, but are not limited to, methyl, methylene, ethyl, ethylene, n-propyl, i-propyl, n-butyl, i-butyl and t-butyl. The term "alkenyl" refers to a straight or branched hydrocarbon containing 2-20 carbon atoms (eg, C 2 -C 10 ) and one or more double bonds. Examples of alkenyl include, but are not limited to, ethenyl, propenyl and allyl. The term "alkynyl" refers to a straight or branched hydrocarbon containing 2-20 carbon atoms (eg, C 2 -C 10 ) and one or more triple bonds. Examples of alkynyl include, but are not limited to, ethynyl, 1-propynyl, 1- and 2-butynyl and 1-methyl-2-butynyl. The term "alkylamino" refers to an -N (R) -alkyl, wherein R can be H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl or heteroaryl. "Alkoxy" means an oxygen moiety having another alkyl substituent. "Alkoxycarbonyl" means an alkoxy group bonded with a carbonyl group. "Oxoalkyl" means an alkyl, also substituted with a carbonyl group. The carbonyl group can be an aldeddo, ketone, ester, amide, acid or chloride acid. [0125] [0126] The term "cidoalkyl" refers to a system of saturated hydrocarbon rings having 3 to 30 carbon atoms (eg, C 3 -C 12 ). Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. The term "cycloalkenyl" refers to a system of non-aromatic hydrocarbon rings having 3 to 30 carbons (eg, C 3 -C 12 ) and one or more double bonds. Examples include cyclopentenyl, cyclohexenyl and cycloheptenyl. The term "heterocycloalkyl" refers to a ring system of 5-8 membered non-aromatic, bi-cyclic rings of 8-12 membered members or 11-14 membered tricyclic members having one or more heteroatoms (such as O, N, S, P or Se). Examples of heterocycloalkyl groups include, but are not limited to, piperazinyl, pyrrolidinyl, dioxanyl, morpholinyl and tetrahydrofuranyl. The term "heterocycloalkenyl" refers to a system of monodilic rings of 5-8 non-aromatic, 8- membered or tridical members of 11-14 members having one or more heteroatoms (such as O, N, S, P or Se) and one or more double bonds. [0127] [0128] The term "aryl" refers to a system of 6-carbon, 10-carbon, tricyclic, 14-carbon monodilic aromatic rings. Examples of aryl groups include, but are not limited to, phenyl, naphthyl and anthracenyl. The term "heteroaryl" refers to a system of monodilic rings of 5-8 aromatic members, 8-12 membered bidclics or 11-14 membered tridicic members having one or more heteroatoms (such as O, N, S, P or He). Examples of heteroaryl groups include pyridyl, furyl, imidazolyl, benzimidazolyl, pyrimidinyl, thienyl, quinolinyl, indolyl and thiazolyl. [0129] [0130] The aforementioned alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, alkylamino, aryl and heteroaryl include both substituted and unsubstituted moieties. Possible substituents on alkylamino, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl and heteroaryl include, but not limited to , C 1 -C 10, alkenyl C 2 -C 10 alkynyl , C 2 -C 10, cycloalkyl C 3 -C 20, C 3 -C 20 cycloalkenyl, heterocycloalkyl C 1 -C 20 heterocycloalkenyl C1 - C20, C1 - C10 alkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, amino, C1 - C10 alkylamino, arylamino , hydroxy, halo, oxo (O =), thioxo (S =), thio, silyl, C 1 -C 10 alkyl, thio, arylthio, C 1 -C 10 alkyl-sulfonyl, arylsulfonyl, acylamino, aminoacyl, aminothioacyl, amidino , mercapto, amido, thiourephd, thiocyanate, sulfonamido, guanidine, urefdo, cyano, nitro, acyl, thioacyl, acyloxy, carbamido, carbamyl, carboxyl and carboxylic ester. On the other hand, the possible substituents on the alkyl, alkenyl or alkynyl include all the aforementioned substituents, except C 1 -C 10 alkyl. Cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl and heteroaryl may also be fused together. [0131] [0132] "Amino" means a nitrogen residue that has two other substituents, where each substituent has a hydrogen atom or alpha carbon bonded with nitrogen. Unless otherwise indicated, the compounds of the invention containing amino moieties may include their protected derivatives. Suitable protecting groups for amino moieties include acetyl, tert-butoxycarbonyl, benzyloxycarbonyl, and the like. [0133] [0134] "Aromatic" means a residue in which the constituent atoms form a system of unsaturated rings, all the atoms in the ring system are sp2 hybridized and the total amount of pi electrons is equal to 4n + 2. An aromatic ring can be such that the ring atoms are only carbon atoms or can include carbon and non-carbon atoms (see heteroaryl). [0135] [0136] "Carbamoflo" means the radical -OC (O) NR to R b , where R a and R b are each, independently, two other substituents where a hydrogen or carbon atom is alpha with respect to nitrogen. It is noted that carbamoflo residues can include their protected derivatives. Examples of suitable protecting groups for carbamoflo moieties include acetyl, tert-butoxycarbonyl, benzyloxycarbonyl, and the like. It is noted that both unprotected and protected derivatives are within the scope of the invention. [0137] [0138] "Carbonyl" means the radical -C (O) -. It is noted that the carbonyl radical can also be substituted with a variety of substituents to form different carbonyl groups including acids, acid halides, amides, esters and ketones. [0139] [0140] "Carboxi" means the radical -C (O) O-. It is noted that the compounds of the invention containing carboxy moieties can include their protected derivatives, ie, where the oxygen is replaced with a protecting group. Suitable protecting groups for carboxy moieties include benzyl, tert-butyl and the like. [0141] [0142] "Ciano" means the radical -CN. [0143] [0144] "Halo" means fluoro, chloro, bromo or iodo. [0145] [0146] "Alkyl halosubstituted", as an isolated group or part of a larger group, means "alkyl" substituted with one or more "halo" atoms, when such terms are defined in this application. Halo-substituted alkyl includes haloalkyl, dihaloalkyl, trihaloalkyl, perhaloalkyl, and the like. [0147] [0148] "Hydroxy" means the -OH radical. [0149] [0150] "Derivative of imine" means a derivative comprising the residue -C (NR) -, wherein R comprises an atom of hydrogen or alpha carbon with respect to nitrogen. [0151] [0152] "Isomeros" means any compound that has the same molecular formulas but differ in the nature or sequence of union of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are called "stereoisomers." The stereoisomers that are not mirror images of others are determined "diastereomers" and the stereoisomers that are non-superimposable mirror images are called "enantiomers" or sometimes "optical isomers". A carbon atom bound with four non-identical substituents is termed a "chiral center". A compound with a chiral center has two enantiomeric forms of opposite chirality. A mixture of two enantiomeric forms is called a "racemic mixture". [0153] "Nitro" means the radical -NO 2 . [0154] [0155] "Protected derivatives" means derivatives of inhibitors, wherein a site or reactive sites are blocked with protecting groups. The protected derivatives are useful in the preparation of inhibitors or in themselves can be active as inhibitors. A comprehensive list of appropriate protective groups can be found in T. W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, 1999. [0156] [0157] "Substituted or unsubstituted" means that a given moiety may consist of only hydrogen substituents through available valencies (not substituted) or may also comprise one or more non-hydrogen substituents through available (substituted) valencies that are not specified from another way by the name of the rest given. [0158] [0159] "Sulfur" means -S-R, wherein R is H, alkyl, carbocycle, heterocycle, carbocycloalkyl or heterocycloalkyl. Particular sulfide groups are mercapto, alkyl sulfide, for example, methyl sulfide (-S-Me); aryl sulfide, for example, phenyl sulfide; Aralkyl sulfide, for example, benzyl sulfide. [0160] [0161] "Sulfinyl" means the radical -S (O) -. It is noted that the sulfinyl radical can also be substituted with a variety of substituents to form different sulfinyl groups including sulfuric acids, sulfinamides, sulfinyl esters and sulfoxides. [0162] [0163] "Sulfonyl" means the radical -S (O) (O) -. It is noted that the sulfonyl radical can also be substituted with a variety of substituents to form different sulfonyl groups including sulfonic acids, sulfonamides, sulfonate esters and sulfones. [0164] [0165] "Thiocarbonyl" means the radical -C (S) -. It is noted that the thiocarbonyl radical can also be substituted with a variety of substituents to form different thiocarbonyl groups including thioacids, thioamides, thioesters and thioketones. [0166] [0167] "Animal" includes humans, non-human mammals (e.g., dogs, cats, rabbits, cows, horses, sheep, goats, pigs, deer, and the like) and not mammals (e.g., birds, and the like). [0168] [0169] "Bioavailability" as used herein is the fraction or percentage of a dose administered from a drug or pharmaceutical composition that reaches intact systemic circulation. In general, when a medication is administered intravenously, its bioavailability is 100%. However, when a medication is administered via other routes (for example, the oral route), its bioavailability decreases (for example, due to incomplete absorption and first pass metabolism). Methods to improve bioavailability include the pharmacological method, salt synthesis, particle size reduction, complexation, change in physical form, solid dispersions, spray drying and hot melt extrusion. [0170] [0171] "Disease" specifically includes any unhealthy condition of an animal or its part and includes an unhealthy condition that may be the cause or incident of a medical or veterinary therapy applied to that animal, that is, the "side effects" of such therapy. [0172] [0173] "Pharmaceutically acceptable" means that which is useful for preparation a pharmaceutical composition which is generally safe, non-toxic and neither biologically undesirable nor otherwise undesirable and includes that which is acceptable for veterinary use, as well as human pharmaceutical use. [0174] [0175] "Pharmaceutically acceptable salts" means salts of compounds of the present invention which are pharmaceutically acceptable, as defined above and which possess the desired pharmacological activity. These salts include salts by the addition of acids formed with inorganic acids or with organic acids. Pharmaceutically acceptable salts also include salts by addition of bases that can be formed when the acidic protons present are capable of reacting with inorganic or organic bases. [0176] [0177] "Profarmaco" means a compound that is metabolically convertible in vivo to an inhibitor according to the present invention. For example, an inhibitor comprising a hydroxyl group can be administered as an ester which is converted by hydrolysis in vivo into the hydroxyl compound. [0178] [0179] "Farmacoforo", as defined by The International Union of Pure and Applied Chemistry, is a set of steric and electronic features that is necessary to ensure optimal supramolecular interactions with a specific biological target and to trigger (or block) its biological response. For example, camptothecin is the Pharmacopoeia of well-known drugs topotecan and irinotecan. As another example, the nitrogenated mustard pharmacophore has a typical formula of -N (CH 2 CH 2 X ) 2 or its N-oxide analogues wherein X is a leaving group such as halo. Anticancer drugs containing a nitrogen mustard include, but are not limited to, melphalan, bendamustine, cyclophosphamide, PX-478, TH-302, PR-104, ifofamide, etc. [0180] [0181] "Pharmaceutically acceptable carrier" means a non-toxic solvent, dispersant, excipient, adjuvant or other material that is mixed with the compound of the present invention in order to allow the formation of a pharmaceutical composition, ie, a dosage form capable of administering to the patient. Examples of pharmaceutically acceptable carrier include appropriate polyethylene glycol (e.g., PEG400), surfactant (e.g., Cremophor), or cyclopolysaccharide (e.g., hydroxypropyl p-cyclodextrin or sulfobutylether p-cyclodextrins), polymer, liposome, micelle, nanosphere, etc. . [0182] [0183] "Stability" in general refers to the duration in which a drug retains its properties without losing potency. Sometimes, it is mentioned as a useful life. Factors that affect the stability of the drug include, among other things, the chemical structure of the drug, the impurity in the formulation, the pH, the moisture content, as well as the environmental factors such as temperature, oxidation, light and relative humidity. Stability can be improved by providing appropriate chemical and / or crystalline modifications (eg, surface modifications that can change hydration kinetics, different crystals that may have different properties), excipients (eg, any other than the active substance in the dosage form), packaging conditions, storage conditions, etc. [0184] [0185] "Therapeutically effective amount" of a composition described herein is understood as an amount of the composition that confers a therapeutic effect on the subject treated, in a reasonable benefit / risk ratio applicable to any medical treatment. The therapeutic effect may be objective (that is, measurable by some test or marker) or subjective (ie, the subject gives an indication of an effect or feels an effect). An effective amount of the composition described above may range from about 0.1 mg / kg to about 500 mg / kg, preferably from about 0.2 to about 50 mg / kg. Effective doses will also vary according to the route of administration, as well as the possibility of coutilization with other agents. It will be understood, however, that the total daily dose of the compositions of the present invention will be decided by the treating physician within the scope of good medical judgment. The therapeutically effective dose level is specific for any particular patient will depend on a variety of factors including the disorder in treatment and the severity of the disorder; the activity of the specific compound used; the specific composition used; age, body weight, general health, sex and the patient's diet; the time of administration, the route of administration and the rate of excretion of the specific compound used; the duration of the treatment; the drugs used in combination or contemporaneously with the specific compound employed; and similar factors well known in the medical arts. [0186] [0187] As used herein, the term "treating" refers to administering a compound to a subject having a neoplastic or immune disorder or having a symptom or a predisposition to it, in order to cure, heal, alleviate, mitigate, alter, remedy, improve, increase or affect the disorder, the symptoms or the predisposition to the disorder. The expression "an effective amount" refers to the amount of the active agent that is required to confer the intended therapeutic effect on the subject. The effective amounts may vary, as recognized by those skilled in the art, according to the route of administration, the use of excipients and the possibility of coutilization with other agents. A "subject" refers to a human being and a non-human animal. Examples of a non-human animal include all vertebrates, e.g., mammals, such as non-human primates (in particular, higher primates), dogs, rodents (e.g., rat or rat), guinea pig, cats and non-mammals such as birds, amphibians, reptiles, etc. In a preferred embodiment, the subject is a human being. In another embodiment, the subject is an experimental or animal animal appropriate as a disease model. [0188] [0189] GENERAL [0190] [0191] "Combination therapy" includes the administration of the subject compositions of the present invention in another combination with other biologically active ingredients (such as, but not limited to, a second agent and different antineoplastic agent) and non-pharmaceutical therapies (such as, but not limited to) , surgery or radiotherapy). For example, the compositions of the invention can be used in combination with other pharmaceutically active compounds or non-pharmacological therapies, preferably, compounds that are capable of improving the effect of the compositions of the invention. The compositions of the invention can be administered simultaneously (as a simple preparation or separate preparation) or sequentially to other therapies. In general, a combination therapy provides for the administration of two or more drugs / treatments during a single cycle or therapeutic course. [0192] [0193] In one embodiment, the compositions of the invention are administered in combination with one or more of the traditional chemotherapeutic agents. Traditional chemotherapeutic agents comprise a wide range of therapeutic treatments in the oncological field. These agents are administered in various stages of the disease in order to reduce tumors, destroy the remaining cancer cells that remain after surgery, induce remission, maintain remission and / or alleviate the symptoms related to cancer or its treatment . Those of such agents include alkylating agents such as nitrosureas (e.g., carmustine, lomustine and streptozocin), ethylene imines (e.g., thiotepa, hexamethylmelanine), alkyl sulfonates (e.g., busulfan), hydrazines, and triazines (e.g., altretamine, procarbazine, dacarbazine, and temozolomide) and platinum-based agents (e.g., carboplatin, cisplatin, and oxaliplatin) ); plant alkaloids such as podophyllotoxins (e.g., etoposide and teniposide), taxanes (e.g., paclitaxel and docetaxel), vinca alkaloids (e.g., vincristine, vinblastine and vinorelbine); antitumor antibiotics such as chromomycins (eg, dactinomycin and plicamycin), anthracyclines (eg, doxorubicin, daunorubicin, epirubicin, mitoxantrone and idarubicin) and miscellaneous antibiotics such as mitomycin and bleomycin; antimetabolites such as folic acid antagonists (e.g., methotrexate), pyrimidine antagonists (e.g., 5-fluorouracil, foxuridine, cytarabine, capecitabine, and gemcitabine), purine antagonists (e.g., 6-mercaptopurine and 6-thioguanine) and adenosine deaminase inhibitors (e.g., cladribine, fludarabine, nelarabine, and pentostatin); topoisomerase inhibitors such as topoisomerase I inhibitors (topotecan, irinotecan), topoisomerase II inhibitors (eg, amsacrine, etoposide, etoposide phosphate, teniposide) and miscellaneous antineoplastic drugs such as ribonucleotide reductase inhibitors (hydroxyurea), inhibitor of adrenocortical steroid (mitotane), antimicrotubular agents (estramustine) and retinoids (bexarotene, isotretinoma, tretinoma (ATRA). [0194] [0195] In one aspect of the invention, the compositions can be administered in combination with one or more target anticancer agents that modulate the protein kinases involved in various disease states. Examples of such kinases may include ABL1, ABL2 / ARG, ACK1, AKT1, AKT2, AKT3, ALK, ALK1 / ACVRL1, ALK2 / ACVR1, ALK4 / ACVR1B, ALK5 / TGFBR1, ALK6 / BMPR1B, AMPK (A1 / B1 / G1 ), AMPK (A1 / B1 / G2), AMPK (A1 / B1 / G3), AMPK (A1 / B2 / G1), AMPK (A2 / B1 / G1), AMPK (A2 / B2 / G1), AMPK (A2 / B2 / G2), ARAF, ARK5 / NETAK1, ASK1 / MAP3K5, ATM, Aurora A, Aurora B, Aurora C, AXL, BLK, BMPR2, BMX / ETK, BRAF, BRK, BRSK1, BRSK2, BTK, CAMKIa, CAMKIb , CAMKId, CAMKIg, CAMKIla, CAMKIIb, CAMKIld, CAMKIIg, CAMK4, CAMKK1, CAMKK2, CDC7-DBF4, CDKI-cyclin A, CDKI-cyclin B, CDKI-cyclin E, CDK2-cyclin A, CDK2-cyclin A1, CDK2- cyclin E, CDK3-cyclin E, CDK4-cyclin D1, CDK4-cyclin D3, CDK5-p25, CDK5-p35, CDK6-cyclin D1, CDK6-cyclin D3, CDK7-cyclin H, CDK9-cyclin K, CDK9-cyclin T1 , CHK1, CHK2, CK1a1, CK1d, CKIepsilon, CK1g1, CK1g2, CK1g3, CK2a, CK2a2, c-KIT, CLK1, CLK2, CLK3, CLK4, c-MER, c-MET, COT1 / MAP3K8, CSK, c-SRC , CTK / MATK, DAPK1, DAPK2, DCAMKL1, DCAMKL2, DDR1, DDR2, DLK / MAP3K12, DMPK, DMPK2 / CDC42BPG, DNA-PK, DRAK1 / STK17A, DYRK1 / DYRK1A, DYRK1B, DYRK2, DYRK3, DYRK4, EEF2K, EGFR, EIF2AK1, EIF2AK2, EIF2AK3, EIF2AK4 / GCN2, EPHA1, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, ERBB2 / HER2, ERBB4 / HER4, ERK1 / MAPK3, ERK2 / MAPK1, ERK5 / MAPK7, FAK / PTK2, FER, FES / FPS, FGFR1, FGFR2, FGFR3, FGFR4, FGR, FLT1 / VEGFR1, FLT3, FLT4 / VEGFR3, FMS, FRK / PTK5, FYN, GCK / MAP4K2, GRK1, GRK2, GRK3, GRK4, GRK5, GRK6, GRK7, GSK3a, GSK3b, haspin, HCK, HGK / MAP4K4, HIPK1, HIPK2, HIPK3, HIPK4, HPK1 / MAP4K1, IGF1R, IKKa / CHPTK, IKKb / IKBKB, IKKe / IKBKE, IR, IRAKI, IRAK4, IRR / INSRR, ITK, JAK1, JAK2, JAK3, JNK1, JNK2, JNK3, KDR / VEGFR2, KHS / MAP4K5, LATS1, LATS2, LCK, LCK2 / ICK, LKB1, LIMK1, LOK / STKIO, LRRK2, LYN, LYNB, MAPKAPK2, MAPKAPK3, MAPKAPK5 / PRAK, MARK1, MARK2 / PAR-1Ba, MARK3, MARK4, MEK1, MEK2, MEKK1, MEKK2, MEKK3, MELK, MINK / MINK1, MKK4, MKK6, MLCK / MYLK, MLCK2 / MYLK2, MLK1 / MAP3K9, MLK2 / MAP3K10, MLK3 / MAP3K11, MNK1, MNK2, MRCKa /, CDC42BPA, MRCKb /, CDC42BPB, MSK1 / RPS6KA5, MSK2 / RPS6KA4, MSSK1 / STK23, MST1 / STK4, MST2 / STK3, MS T3 / STK24, MST4, mTOR / FRAP1, METSK, MYLK3, MYO3b, NEK1, NEK2, NEK3, NEK4, NEK6, NEK7, NEK9, NEK11, NIK / MAP3K14, NLK, OSR1 / OXSR1, P38a / MAPK14, P38b / MAPK11, P38d / MAPK13, P38g / MAPK12, P70S6K / RPS6KB1, p70S6Kb /, RPS6KB2, PAK1, PAK2, PAK3, PAK4, PAK5, PAK6, PASK, PBK / TOPK, PDGFRa, PDGFRb, PDK1 / PDPK1, PDK1 / PDHK1, PDK2 / PDHK2 , PDK3 / PDHK3, PDK4 / PDHK4, PHKgl, PHKg2, PI3Ka, (p110a / p85a), PI3Kb, (p110b / p85a), PI3Kd, (p110d / p85a), PI3Kg (p120g), PIM1, PIM2, PIM3, PKA, PKAcb, PKAcg, PKCa, PKCb, PKCb2, PKCd, PKCepsilon, PKCa, PKCg, PKCiota, PKCmu / PRKDl, PKCnu / PRKD3, PKCteta, PKC2, PKD2 / PRKD2, PKG1a, PKG1b, PKG2 / PRKG2, PKN1 / PRK1, PKN2 / PRK2, PKN3 / PRK3, PLK1, PLK2, PLK3, PLK4 / SAK, PRKX, PYK2, RAF1, RET, RIPK2, RIPK3, RIPK5, ROCK1, ROCK2, RON / MST1R, ROS / ROS1, RSK1, RSK2, RSK3, RSK4, SGK1, SGK2, SGK3 / SGKL, SIK1, SIK2, SLK / STK2, SNARK / NETAK2, SRMS, SSTK / TSSK6, STK16, STK22D / TSSK1, STK25 / YSK1, STK32b / YANK2, STK32c / YANK3, STK33, STK38 / NDR1, STK38L / NDR2, STK39 / STLK3, SRPK1, SRPK2, SYK, TAK1, TAOK1, TAOK2 / TAO1, TAOK3 / JIK, TBK1, TEC, TESK1, TGFBR2, TIE2 / TEK, TLK1, TLK2, TNIK, TNK1, TRKA, TRKB, TRKC, TRPM7 / CHAK1, TSSK2, TSSK3 / STK22C, TTBK1, TTBK2, TTK, TXK , TYK1 / LTK, TYK2, TYRO3 / SKY, ETLK1, ETLK2, ETLK3, VRK1, VRK2, WEE1, WNK1, WNK2, WNK3, YES / YES1, ZAK / MLTK, ZAP70, ZIPK / DAPK3, KINASE, METTANTS, ABL1 (E255K ), ABL1 (F317I), ABL1 (G250E), ABL1 (H396P), ABL1 (M351T), ABL1 (Q252H), ABL1 (T315I), ABL1 (Y253F), ALK (C1156Y), ALK (L1196M), ALK (F1174L) ), ALK (R1275Q), BRAF (V599E), BTK (E41K), CHK2 (I157T), c-Kit (A829P), c-KIT (D816H), c-KIT (D816V), c-Kit (D820E), c-Kit (N822K), C-Kit (T670I), c-Kit (V559D), c-Kit (V559D / V654A), c-Kit (V559D / T6701), C-Kit (V560G), c-KIT ( V654A), C-MET (D1228H), C-MET (D1228N), C-MET (F1200I), c-MET (M1250T), C-MET (Y1230A), C-MET (Y1230C), C-MET (Y1230D) ), C-MET (Y1230H), c-Src (T341M), EGFR (G719C), EGFR (G719S), EGFR (F858R), EGFR (L861Q), EGFR (T790M), EGFR, (F858R, T790M), EGFR (d746-750 / T790M), EGFR (d746-750), EGFR (d747-749 / A750P), EGFR (d747-752 / P753S), EGFR (d752-759), FGFR1 (V561M), FGFR2 (N549H) ), FGFR3 (G697C), FGFR3 (K650E), FGFR3 (K650M), FGFR4 (N535K), FGFR4 (V550E), FGFR4 (V550L), FLT3 (D835Y), FLT3 (ITD), JAK2 (V617F), LRRK2 (G2019S) ), LRRK2 (I2020T), LRRK2 (R1441C), p38a (T106M), PDGFRa (D842V), PDGFRa (T6741), PDGFRa (V561D), RET (E762Q), RET (G691S), RET (M918T), RET (R749T) ), RET (R813Q), RET (V804L), RET (V804M), RET (Y791F), TIF2 (R849W), TIF2 (Y897S) and TIF2 (Y1108F). [0196] [0197] In another aspect of the invention, the subject compositions can be administered in combination with one or more target anticancer agents that modulate objects, pathways or non-kinase processes. These objects, routes or processes include heat shock proteins (eg, HSP90), poly-ADP (adenosine diphosphate) -ribose polymerase (PARP), hypoxia-inducible factors (HIF), proteasome, Wnt / Hedgehog / Notch signaling proteins, TNF-alpha , matrix metalloproteinase, farnesyltransferase, apoptotic pathway (eg, Bcl-xL, Bcl-2, Bcl-w), histone deacetylases (HDAC), histone acetyltransferases (HAT) and methyltransferase (eg, histone lysine methyltransferases, histone arginine methyltransferase , DNA methyltransferase). [0198] [0199] In another aspect of the invention, the compositions of the invention are administered in combination with one or more other anticancer agents that include hormonal therapies (eg, tamoxifen, fulvestrant, clomiphene, anastrozole, exemestane, formestane, letrozole, etc.) of vascular disruption, gene therapy, RNAi cancer therapy, chemoprotective agents (eg, amphotina, mesna, and dexrazoxane), antibody conjugate (eg, brentuximab vedotin, ibritumomab thioxetane), cancer immunotherapy such as interleukin-2, vaccines anticancer (eg, sipuleucel-T) or monoclonal antibodies (eg, bevacizumab, alemtuzumab, rituximab, trastuzumab). [0200] [0201] In another aspect of the invention, the subject compositions are administered in combination with radiotherapy or surgery. Common radiation is commonly delivered internally (implanting radioactive material near the cancer site) or externally from a machine that uses photon radiation (x-rays or gamma rays) or particle radiation. When the combined therapy also comprises radiation treatment, the radiation treatment can be carried out at any appropriate time, provided that a beneficial effect of the coercion of the combination of the therapeutic agents and the radiation treatment is achieved. For example, in appropriate cases, the beneficial effect is achieved even when the radiation treatment is temporarily removed from the administration of the therapeutic agents, perhaps in days or even weeks. [0202] [0203] In certain preferred embodiments, the compositions of the invention are administered in combination with one or more of radiotherapy, surgery or anticancer agents including, DNA damaging agents, antimetabolites, topoisomerase inhibitors, microtubule agents, EGFR inhibitors, inhibitors of HER2, inhibitors of VEGFR2, inhibitors of BRAF, inhibitors of Bcr-Ab1, inhibitors of PDGFR, inhibitors of ALK, inhibitors of PLK, inhibitors of MET, epigenetic agents, inhibitors of HSP90, inhibitors of PARP, inhibitors of CHK, inhibitor of aromatase , estrogen receptor antagonist and antibodies directed to VEGF, HER2, EGFR, CD50, CD20, CD30, CD33. [0204] [0205] In certain preferred embodiments, the compositions of the invention are administered in combination with one or more of abarelix, abiraterone acetate, aldesleukin, alemtuzumab, altretamine, anastrozole, asparaginase, bevacizumab, bexarotene, bicalutamide, bleomycin, bortezombi, brentuximab vedotin, busulfan, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofaphine, clomiphene, crizotinib, cyclophosphamide, dasatinib, liposomal daunorubicin, decitabine, degarelix, denileukin diftitox, denileukin diftitox, denosumab, docetaxel, doxorubicin, liposomal doxorubicin, epirubicin, mesylate, eribulin, erlotinib, estramustine, etoposide phosphate, everolimus, exemestane, fludarabine, fluorouracil, fotemustine, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelin acetate, hydroxyurea, ibritumomab tiuxetane, idarubicin, ifosfamide, imatinib mesylate, interferon alfa 2a, ipilimum ab, ixabepilone, lapatinib ditosylate, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lomustine, mechlorethamine, melphalan, methotrexate, mitomycin C, mitoxantrone, nelarabine, nilotinib, oxaliplatin, paclitaxel, partroula bound to the paclitaxel protein, pamidronate, panitumumab, pegaspargase, peginterferon alfa-2b, pemetrexed disodium, pentostatin, raloxifene, rituximab, sorafenib, streptozocin, sunitinib maleate, tamoxifen, temsirolimus, teniposide, thalidomide, toremifene, tositumomab, trastuzumab, tretinoma, uramustine, vandetanib, vemurafenib, vinorelbine, zoledronate, radiotherapy or surgery. [0206] [0207] A wide variety of administration methods can be used in conjunction with the compositions of the present invention. The compositions of the present invention can be administered or coadministered orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, trans-orally, intranasally, liposomally, by inhalation, vaginally, intraocularly, by local delivery (e.g. , by catheter or stent), by subcutaneous, intra-adipose, intra-articular or intrathecal route. The compositions according to the invention can also be administered or co-administered in slow release dosage forms. The compositions may be in gaseous, liquid, semi-solid or solid form, formulated in an appropriate manner by the route of administration to be used. For oral administration, suitable solid oral formulations include tablets, capsules, pellets, granules, pellets, sachets and effervescent powders, and the like. [0208] [0209] Suitable liquid oral formulations include solutions, suspensions, dispersions, emulsions, oils, and the like. For parenteral administration, reconstitution of a lyophilized powder is normally used. [0210] [0211] The invention also comprises compositions for the prevention or treatment of a neoplastic disease or immune disease. In one embodiment, the invention relates to a composition for treating a neoplastic disease or immune disease in a subject in need of treatment comprising administering to said subject a therapeutically effective amount of a composition of the invention. In one embodiment, the invention also provides the use of a composition of the invention in the manufacture of a medicament for stopping or reducing a neoplastic disease or immune disease. [0212] Neoplasic disease includes lung cancer, head and neck cancer, central nervous system cancer, prostate cancer, testicular cancer, colorectal cancer, pancreatic cancer, cancer of the stomach, stomach cancer, cancer of the biliary tract, esophageal cancer, gastrointestinal stromal cancer, breast cancer, cervical cancer, ovarian cancer, uterine cancer, leukemia, lymphomas, multiple myeloma, melanoma, basal cell carcinoma, squamous cell carcinoma, bladder cancer, renal cancer, sarcoma, mesothelioma, thymoma, myelodysplastic syndrome and myeloproliferative disease. [0213] [0214] It is well known that immunosuppression is one of the main side effects of many conventional chemotherapies. For example, at low doses, cyclophosphamide can be used to treat immune diseases such as multiple sclerosis, rheumatoid arthritis and the suppression of transplant rejections (Emadi A, et al., Nat Rev Clin Oncol., 2009 Nov; 6 (11). : 638-47; Perini P, et al., Neurol Sci., 2008 Sep; 29 Suppl 2: S233-4.) And is also widely used in the "conditioning" and "mobilization" regimens of bone marrow transplantation, and for the treatment of severe refractory autoimmune conditions, such as systemic lupus erythematosus (SLE), minimal change disease, severe rheumatoid arthritis, Wegener's granulomatosis (with the trademark Cytoxan), scleroderma and multiple sclerosis (with the trademark Revimmune). In addition, HDAC recently emerged as a promising target for treating immune disease [Szyf M. Clin Rev Allergy Immunol. 2010 Aug; 39 (1): 62-77]. Therefore, it is not difficult to imagine that the compositions of the present invention could be used for the treatment of an immune disease. [0215] [0216] In a preferred embodiment, the immune disease is selected from the group consisting of the rejection of transplanted organs and tissues, a graft versus host disease, a non-autoimmune inflammatory disease and an autoimmune disease, wherein said autoimmune disease is selected from the group that consists of acute disseminated encephalomyelitis, Addison's disease, ankylosing spondylitis, antiphospholipid antibody smdrome, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, bullous pemphigoid, celiac disease, Chagas disease, chronic obstructive pulmonary disease, Strauss, dermatomyositis, Crohn's disease, diabetes mellitus type 1, endometriosis, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, suppurative hidradenitis, idiopathic thrombocytopenic purpura, interstitial cystitis, lupus erythematosus, morphea, sclerosis multiple, myasthenia gravis, na rcolepsy, neuromyotonia, pemphigus vulgaris, pernicious anemia, polymyositis, primary biliary cirrhosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, schizophrenia, scleroderma, temporal arteritis, vasculitis, vitiligo and Wegener's granulomatosis. [0217] [0218] METHODS OF SYNTHESIS [0219] [0220] The compounds of the invention can be prepared by any process known in the art. The necessary starting materials can be obtained by means of standard procedures of organic chemistry. The compounds and processes of the present invention will be better understood in connection with the following representative synthesis schemes which are only intended as an illustration. [0221] [0222] [0223] [0224] [0225] In general, the compounds of the formula (I) can be prepared according to the general scheme 1 below. Xi, X 2 , Q, Z and m in general scheme 1 are the same as those described in the section of the previous Synthesis. [0226] [0227] The starting material (1), a 5-10 membered nitro-substituted ring, can be coupled with a suitable carboxylic ester to give the intermediate (2), which can then be reduced, for example, with H 2 , Pd / C, in an amino-substituted intermediate (3). The resulting intermediate (3) can react with oxirane to easily give intermediate (4), which can be converted into intermediate (5) in high yield by reaction with a chlorinating reagent such as thionyl chloride or phosphorus pentachloride. Finally, the hydroxylamination of the intermediate (5) in NH 2 OH can result in the target compound (6). [0228] [0229] The compounds of the formula (II) [0230] general scheme 2 below. X 1 , R 1 , R 2 , Z and m in the general scheme 2 are the same as those described in the previous Smtesis section. [0231] [0232] [0233] [0234] [0235] The starting material (1), a substituted 2,4-dinitroaniline, can be coupled with an appropriate acyl chloride to give an N-acylated intermediate (2). The alkylation of N-acylated intermediate (2) with an alkylating agent such as iodomethane, methyl methalate, dimethyl sulfate will lead to a dinitroaromatic intermediate (3). The reduction of the intermediate (3), for example, with H 2 , Pd / C, followed by dehydration with acid will form an intermediary of benzimidazole (4). The intermediate (4) can react with oxirane to easily achieve the intermediate (5), which is can be converted into intermediate (6) with high yield by reaction with a chlorinating reagent such as thionyl chloride or phosphorus pentachloride. Finally, the hydroxylamination of the intermediate (6) in NH 2 OH can result in the target compound represented by the formula (II). [0236] [0237] [0238] [0239] [0240] The compound of the formula (III) can be prepared according to the general scheme 3 below. [0241] [0242] [0243] [0244] [0245] The starting material (1), a 2,4-dinitroaniline can be coupled with an appropriate acyl chloride to give an N-acylated intermediate (2). The alkylation of the N-acylated intermediate with an alkylating agent such as dimethyl sulfate will lead to a dinitroaromatic intermediate (3). The reduction of the dinitroaromatic intermediate (3), for example, with H 2 , Pd / C, followed by dehydration with acid will form the intermediate of benzimidazole (4). The intermediate (4) can react with oxirane to easily achieve the intermediate (5), which can be converted into the intermediate (6) in high yield by reaction with a chlorinating reagent such as thionyl chloride. Finally, the hydroxylamination of the intermediate (6) in NH 2 OH can result in the target compound of formula (III). [0246] [0247] [0248] [0249] [0250] Alternatively, the compound of the formula (III) can be prepared according to the general scheme 4 below. [0251] [0252] [0253] The starting material (1), a 2,4-dinitroaniline can be coupled with an appropriate acyl chloride to give an N-acylated intermediate (2). Alkylation of the N-acylated intermediate with an alkylating agent such as dimethyl sulfate will lead to a dinitroaromatic intermediate (3). The reduction of the dinitroaromatic intermediate (3), for example with H 2 , Pd / C, followed by dehydration with acid will form the intermediate of benzimidazole (4). The intermediate (4) can react with oxirane to easily achieve the intermediate (5), which can be converted into the intermediate (6) in high yield by reaction with a chlorinating reagent such as thionyl chloride. The hydrolysis of the intermediate (6) in concentrated HCl will lead to the carboxylic acid intermediate (7), which can be coupled with O- (tetrahydro-2H-pyran-2-yl) hydroxylamine to obtain the intermediate (8). Finally, the hydrolysis of the intermediate (8) in acid will result in the target compound of the formula (III). [0254] [0255] [0256] [0257] [0258] Alternatively, the compound of formula (III) can be prepared according to General Scheme 5 below. [0259] [0260] [0261] The starting material (1), 1-chloro-2,4-dinitrobenzene can be coupled with an alkylamine to give the intermediate (2), which can be reduced in the intermediate (3) in yield. The intermediate (3) can be acylated to form the intermediate (4), which will undergo a dehydration reaction with acid to obtain the intermediate of benzimidazole (5). The intermediate (5) can then be reduced, for example, with H 2 , Pd / C, in an amino-substituted intermediate (6). The resulting intermediate (6) can react with oxirane to easily achieve intermediate (7), which can be converted into intermediate (8) in high yield by reaction with a chlorinating reagent such as thionyl chloride or phosphorus pentachloride. Finally, the hydroxylamination of the intermediate (8) in NH 2 OH can result in the target compound of the formula (III). [0262] [0263] [0264] [0265] [0266] Alternatively, the compound of formula (III) was prepared according to General scheme 6 below. [0267] [0268] [0269] [0270] [0271] The starting material (1), 1-chloro-2,4-dinitrobenzene, can be coupled with an alkylamine to give the intermediate (2), which can be reduced in the intermediate (3) with yield. The intermediate (3) can be acylated to form the intermediate (4), which will undergo a dehydration reaction with acid to obtain the intermediate of benzimidazole (5). The intermediate (5) can then be reduced, for example, with H 2 , Pd / C, in an amino-substituted intermediate (6). The resulting intermediate (6) can react with oxirane to easily achieve intermediate (7), which can be converted into intermediate (8) in high yield by reaction with a chlorinating reagent such as thionyl chloride or phosphorus pentachloride. Hydrolysis of the intermediate (8) in concentrated HCl will lead to the carboxylic acid intermediate (9), which can be coupled with O- (tetrahydro-2H-pyran-2-yl) hydroxylamine to obtain the intermediate (10). Finally, hydrolysis of intermediate (10) in acid will result in the target compound of formula (III). [0272] [0273] EXAMPLES [0274] [0275] Example 1: Preparation of the formulation of the compound of the formula (III) (also called first generation formulation NL-101): [0276] [0277] Solution 1: prepare acetic acid solution at 50% (v / v) in deionized water, store at room temperature; [0278] Solution 2: prepare 0.20% (w / v) solution of NaOH in deionized water, store at room temperature; [0279] Solution 3: prepare 200 mg / ml of compound of formula (III) in Solution 1 (ie, 50% acetic acid): sonication for 10-30 seconds will be very useful to dissolve the compound; [0280] [0281] Finally, add 970 | jL of Solution 2 in 30 | jL of Solution 3, which leads to 6 mg / ml solution of the compound of the formula (III). [0282] Example 2: Preparation of a compound composition of formula (III) with hydroxypropyl p-cyclodextrin (also called NL-101 formulation based on HPpCD): [0283] Solution 1: prepare acetic acid solution at 50% (v / v) in deionized water, store at room temperature; Solution 2: prepare hydroxypropyl p-cyclodextrin at 20% (w / v) by adding 80 mL of deionized water to each 20 grams of hydroxypropyl p-cyclodextrin, vortex for 5 minutes, store at room temperature; [0284] Solution 3: prepare 5% (w / v) solution of NaHCO 3 in deionized water, store at room temperature; NaHCO 3 is used as a pH adjusting agent; [0285] Solution 4: prepare 200 mg / ml of compound of formula (III) in Solution 1 (ie, 50% acetic acid): sonication for 10-30 seconds will be very useful to dissolve the compound; [0286] Solution 5: 1: 1 mixture of Solution 2 and Solution 3; [0287] Add 30 jl of Solution 4 in 970 | jL of Solution 5 and mix well, bringing to 6 mg / ml of compound solution of formula (III), with 10% hydroxypropyl p-cyclodextrin, 1.5% acetic acid , 2.5% NaHCO 3 and pH 6-7; [0288] Solution filtration: the formulations of the compound of formula (III) of step (6) are filtered through a pre-sterilized filter of 0.2 jm with> 98% recovery; [0289] Preparation of a lyophilisate: the formulations of step (7) were lyophilized to form the lyophilisate in the form of a powder. The resulting lyophilized formulation was chemically stable at the following temperatures, -20 ° C, 4 ° C, and room temperature for at least 2 weeks. It can be stored at 4 ° C for more than 2 weeks without decomposition; [0290] Dilution study: the formulations of stage (7) were diluted with deionized water (x 10 times) and were chemically stable and remained in solution without precipitation (> 12 hours). [0291] Example 3: Preparation of a compound composition of formula (III) with sulfobutileter p-cyclodextrin (also called NL-101 formulation based on Captisol ™): [0292] Solution 1: prepare acetic acid solution at 50% (v / v) in deionized water, store at room temperature; Solution 2: prepare sulfobutileter p-cyclodextrin at 20% (w / v) by adding 80 mL of deionized water in each 20 grams of sulfobutileter p-cyclodextrin, vortex for 5 minutes, store at room temperature; [0293] Solution 3: prepare 5% (w / v) solution of NaHCO 3 in deionized water, store at room temperature; NaHCO 3 is used here as a pH adjusting agent; [0294] Solution 4: prepare 200 mg / ml of the compound of formula (III) in Solution 1 (ie, 50% acetic acid): sonication for 10-30 seconds will be useful for dissolving the compound; [0295] Solution 5: 1: 1 mixture of Solution 2 and Solution 3; [0296] Add 30 jl of Solution 4 in 970 jL of Solution 5 and mix well, bringing to 6 mg / ml solution of the compound of formula (III), with 10% sulfobutileter p-cyclodextrin, 1.5% acid acetic, 2.5% NaHCO 3 and pH 6-7; Solution filtration: the formulations of the compound of formula (III) of step (6) are filtered through a pre-sterilized filter of 0.2 jm with> 98% recovery; [0297] Preparation of a lyophilisate: the formulations of step (7) were lyophilized to form the lyophilisate in the form of a powder. The resulting lyophilized formulation was chemically stable at the following temperatures, -20 ° C, 4 ° C, room temperature for at least 2 weeks. It can be stored at 4 ° C for more than 2 weeks without decomposition; [0298] Dilution study: the formulations of stage (7) were diluted with deionized water (x 10 times) and were chemically stable and remained in solution without precipitation (> 12 hours). [0299] Example 4: Tris as an alternative pH adjusting agent: [0300] Tris (CAS #: 77-86-1) is widely used as a component of a pH buffer solution. Tris is used as an excipient in some drugs approved by the FDA. It has a pKa of 8.30. The buffer system of Tris-acetic acid has a pH range of 7-8, therefore, Tris can be an ideal pH adjusting agent for the NF-101 formulation. [0301] We have successfully developed an NL-101 formulation based on HPBCD containing Tris containing with 6 mg / ml of NL-101, 15% of HPBCD, 250 mM of acetic acid, 333 mM of Tris, pH = 7.4 +/- 0.2. The formulation was prepared as follows: [0302] [0303] Solution 1: prepare 200 mg / ml of NL-101 in 50% acetic acid; [0304] [0305] Solution 2: prepare Tris 1 M, then dilute to 0.6666 M: (base Tris, F.W.121.14 g / mol). [0306] [0307] Solution 3: prepare 30% (w / v) of HPBCD in 100 mM sodium acetate buffer (pH = 5.4); [0308] [0309] Solution 4: 1: 1 mixture of Solution 2 and Solution 3. [0310] [0311] Final solution: add 970 pL of solution 4 in 30 pl of solution 1, mix well, bringing to 6 mg / ml of NL-101, 15% of HPBCD, 250 mM of acetic acid, 333 mM of Tris, pH = 7, 4 +/- 0.2. [0312] [0313] In comparison with NaHCO 3 as a pH adjusting agent, it is easier to precisely control the pH value of the NL-101 formulation based on HPBCD containing Tris within the pH range of 7-8, since the formulation that contains Tris is a buffer system of acetic Tris-acid with a theoretical buffer range of 7-8. The neutral pH value of the NL-101 formulation based on HPBCD containing Tris is a clear advantage for future clinical development. [0314] [0315] Example 5: Single dose toxicity study IV in mice with the first generation formulation NL-101: [0316] A single dose of first generation formulation NL-101 (20, 40, 60, 80 or 100 mg / kg) was administered slowly (iv, injection time> 30 seconds) to the mice and the change in body weight was measured during 14 days to evaluate the toxicity of the various doses of NL-101. We found that up to 60 mg / kg of NL-101 did not result in a significant change in body weight. [0317] [0318] However, we find that the first generation formulation has many advantages such as low pH value, potential precipitation after injection i.v. and series of side effects such as tail of mice damaged after injection i.v. More seriously, we sometimes observe that the quick injection i.v. (for example, injection time <5 seconds) of NL-101 can lead to sudden death of the mice. [0319] [0320] Example 6: Single dose IV toxicity study in mice with the HPLC-based formulation NL-101: [0321] [0322] A single dose of the HPLC-based NL-101 formulation (20, 40, 60, 80, 100 or 150 mg / kg) in 10% HPpCD was administered (iv) to mice and the change in body weight was measured during 14 days to evaluate the toxicity of the various doses of NL-101. We found that up to 60 mg / kg of NL-101 did not result in a significant change in body weight. [0323] [0324] We were surprised to find that the HPLC-based NL-101 formulation can significantly reduce cardiotoxicity in vivo. The mice can even survive under rapid injection (t <5 seconds) of 150 mg / kg of NL-101. More importantly, we did not observe a cardiorespiratory stress in mice at a therapeutically effective dose of 60 mg / kg. In addition, this formulation also has many other advantages, such as neutral pH, transparent and stable injection solution, no problem of precipitation after iv injection and no damaged mouse tail after iv injection. Therefore, the NL-101 formulation based on HPpCD will be an ideal formulation for use in NL-101 BAT, PK, in vivo efficacy study and study that allows IND. We are actively developing the NL-101 formulation based on HPpCD for future human clinical assay. [0325] [0326] Example 7: Single dose toxicity study IV in mice with the NL-101 formulation based on Captisol ™: [0327] A single dose of NL-101 formulation based on Captisol ™ (20, 40, 60, 80, 100 or 150 mg / kg) in 10% of Captisol ™ was administered (iv) to mice and the change in body weight was measured. for 14 days to evaluate the toxicity of the various doses of NL-101. We found that up to 60 mg / kg of NL-101 did not result in a significant change in body weight. [0328] [0329] We are pleased to find that the NL-101 formulation based on Captisol ™ can also significantly reduce cardiotoxicity in vivo. The mice can even survive under rapid injection (t <5 seconds) of 150 mg / kg of NL-101. More importantly, we did not observe a cardiorespiratory stress in mice at a therapeutically effective dose of 60 mg / kg. In addition, this formulation also has many other advantages, such as neutral pH, transparent and stable injection solution, no problem of precipitation after iv injection and no damaged mouse tail after iv injection. Therefore, the NL-101 formulation based on Captisol ™ will also be an ideal formulation for use in NL-101 BAT, PK, in vivo efficacy study, study that allows IND, as well as in the future human clinical trial. [0330] [0331] Example 8: Multi-dose IV toxicity study in mice with HPLC-based formulation NL-101: [0332] Multiple doses of the NL-101 formulation based on HPpCD (60 mg / kg) in 10% HPpCD were administered (iv) to mice and the change in body weight was measured to evaluate the toxicity of the various doses of NL-101 . We found that mice can tolerate multiple doses of 60 mg / kg NL-101 well without a significant change in body weight. [0333] For example, mice can be dosed at 60 mg / kg on days 1, 4, 8, 11, 18, 25. Another viable dosing schedule is 60 mg / kg on days 1, 2, 8, 15, 22, 29 . [0334] Example 9: Multi-dose IV toxicity study in mice with the NL-101 formulation based on Captisol ™: Multiple doses of NL-101 formulation based on Captisol ™ (60 mg / kg) in 10% Captisol ™ were administered (iv) to mice and the change in body weight was measured to assess the toxicity of the various doses of NL-101. We found that mice can tolerate multiple doses of 60 mg / kg NL-101 well without a significant change in body weight. For example, mice can be dosed at 60 mg / kg on days 1, 4, 8, 11, 18, 25. Another viable dosing schedule is 60 mg / kg on days 1, 2, 8, 15, 22, 29 . [0335] Example 10: Efficacy of HPLC-based NL-101 formulation in non-small cell human lung cancer A549 xenograft model [0336] Animal: Balb / c mice 5 to 6 weeks old were kept 5 per cage with an air filter cover under light (12 hours light / dark cycle, light switched on at 6:00 hours) and temperature controlled environment ( 22 ± 1 ° C). All animal manipulations were carried out under a sterilized laminar hood. The animals have an ad libitum access to food for Purina mice (Pro Lab PMH 4018, trademark of Agway, Syracuse, N.Y.) and water. These animal studies were carried out in accordance with the "Guidelines for Care and Use of Experimental Animals". [0337] Tumor cell culture: human NSCLC A549 cells were cultured in the appropriate culture medium. The cells were cultured in their phase of logantum growth for the preparation of tumor implant. [0338] Tumor implant: human tumor cells (2.5 to 5.0 x 106 cells) were implanted subcutaneously in 0.2 mL of medium containing 30% of Matrigel in the two flanks of balb / c nu / nu mice through a water of 1 to 2 cm in length of 20 gauge. [0339] Treatments: 2 to 3 weeks after the implantation of tumor cells, animals that developed solid tumors s.c. and were divided into several homogeneous groups (n = 6 animals per group or dose) with respect to the tumor size (100-200 mm3). The animals were dosed i.v. with 60 mg / kg of the following formulation on days 1, 4, 8, 11, 18, 25. [0340] Group of vetucule: 10% HPpCD, 1.5% acetic acid, 2.5% NaHCO 3 ; [0341] Group NL-101: 6 mg / ml, 10% HPpCD, 1.5% acetic acid, 2.5% NaHCO 3 ; [0342] Bendamustine group: 6 mg / ml, 10% HPpCD, 1.5% acetic acid, 2.5% NaHCO 3 . [0343] Efficacy assessment: measurements of subcutaneous solid tumors were made on the day of the first injection and at 4-day intervals thereafter. The two largest perpendicular diameters of each tumor were measured with gauges and the tumor sizes were estimated using the formula: [0344] TV = LxW / 2, where TV: tumor volume; L: long; W: wide. The body weights of the animals were also recorded. The results are presented in the table below. [0345] [0346] [0347] [0348] * p <0.01 vs. control group [0349] The above data shows that the HPLC-based NL-101 composition has excellent in vivo efficacy in an A549 xenograft model without evidence of significant general cytotoxicity and cardiotoxicity. [0350] After an extensive evaluation, the NL-101 formulation based on HPpCD was selected for the study that allows IND.
权利要求:
Claims (22) [1] A pharmaceutical composition comprising (a) a cyclopolysaccharide and (b) a compound of the formula (II) [2] 2. The composition according to claim 1, wherein X 1 is halo and m is 5, 6, 7 or 8. [3] 3. The composition according to claim 1, wherein the compound is represented by the formula (III) [4] The composition according to claim 1, wherein said pharmaceutically acceptable salt is a hydrochloride salt, hydrobromide salt, methanesulfonate, toluenesulfonate, acetate, fumarate, sulfate, bisulfate, succinate, citrate, phosphate, maleate, nitrate, tartrate, benzoate. , bicarbonate, carbonate, sodium hydroxide salt, calcium hydroxide salt, potassium hydroxide salt, tromethamine salt (Tris) or mixtures thereof, preferably a salt of hydrochloride, methanesulfonate, toluenesulfonate, acetate, succinate, citrate, maleate, tartrate or mixtures thereof and most preferably, an acetate salt. [5] 5. The composition according to claim 1, wherein the cyclopolysaccharide is a cyclodextrin. [6] The composition according to claim 5, wherein said cyclodextrin is selected from the group consisting of a-cyclodextrin or one of its derivatives, p-cyclodextrin or one of its derivatives and y-cyclodextrin or one of its derivatives. [7] The composition according to claim 6, wherein said cyclodextrin is p-cyclodextrin or a derivative. [8] The composition according to claim 7, wherein said p-cyclodextrin is a hydroxypropyl p-cyclodextrin or sulfobutylether p-cyclodextrin. [9] 9. The composition according to claim 1, wherein the composition also contains a pH adjusting agent. [10] The composition according to claim 9, wherein said pH adjusting agent is sodium bicarbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, calcium hydroxide, tromethamine (Tris) or mixtures thereof, preferably sodium bicarbonate. sodium, tromethamine (Tris) or mixtures thereof. [11] 11. A composition comprising (a) a cyclodextrin, (b) a compound of the formula (III) [12] The composition according to claim 11, wherein said cyclodextrin is p-cyclodextrin or one of its derivatives, preferably hydroxypropyl p-cyclodextrin or sulfobutylether p-cyclodextrin. [13] The composition according to claim 11, wherein said pharmaceutically acceptable salt is a salt of hydrochloride, methanesulfonate, toluenesulfonate, acetate, succinate, citrate, maleate, tartrate or mixtures thereof, preferably an acetate salt. [14] The composition according to claim 11, wherein said pH adjusting agent is bicarbonate, carbonate, sodium hydroxide, calcium hydroxide, potassium hydroxide, tromethamine, or mixtures thereof, preferably sodium bicarbonate. [15] 15. The composition according to claim 11, wherein said cyclodextrin is a hydroxypropyl p-cyclodextrin or sulfobutylether p-cyclodextrin, said pharmaceutically acceptable salt is an acetate salt and said pH adjusting agent is sodium bicarbonate. [16] 16. The composition according to claim 11, wherein the composition has a pH range of 6.0 to 9.0, preferably 7.0 to 8.0. [17] 17. The composition according to claim 11, wherein the cyclodextrin is present in a concentration of 0.5% to 40% by weight / volume, preferably in a concentration of 2.5% to 20% by weight / volume. [18] 18. A pharmaceutical dosage form comprising a pharmaceutical composition according to claim 11, wherein the pharmaceutical dosage form comprises 5 mg to 500 mg of compound represented by the formula (III). [19] 19. A lyophilized preparation of the composition according to claim 11, wherein the preparation is packaged in a vial or other pharmaceutically acceptable container. [20] 20. A composition according to claim 11 for use in a method of treating a neoplastic disease or an immune disease comprising administering an effective amount of said composition, either alone or in combination with other therapies to a subject in need thereof. . [21] 21. A composition for use in a method according to claim 20, wherein said neoplasic disease is lung cancer, head and neck cancer, central nervous system cancer, prostate cancer, testicular cancer, colorectal cancer, pancreatic cancer, cancer of liver, stomach cancer, biliary tract cancer, esophageal cancer, gastrointestinal stromal cancer, breast cancer, cervical cancer, ovarian cancer, uterine cancer, leukemia, lymphomas, multiple myeloma, melanoma, basal cell carcinoma, carcinoma of the Squamous cells, bladder cancer, renal cancer, sarcoma, mesothelioma, thymoma, myelodysplastic syndrome or myeloproliferative disease. [22] 22. A composition for use in a method according to claim 20, wherein said neoplasic disease is leukemia, lymphomas, multiple myeloma, lung cancer, breast cancer, myelodysplastic syndrome, myeloproliferative disease, pancreatic cancer, liver cancer, cancer of the stomach, esophageal cancer, gastrointestinal stromal tumor, cervical cancer, ovarian cancer, uterine cancer or melanoma.
类似技术:
公开号 | 公开日 | 专利标题 ES2662775T3|2018-04-09|Pharmaceutical composition containing an HDAC inhibitor and a cyclopolysaccharide US10377755B2|2019-08-13|BCL-2 inhibitors ES2645271T3|2017-12-04|New therapeutic agents US11236089B2|2022-02-01|Substituted pyrrolopyridines as ATR inhibitors WO2019165204A1|2019-08-29|1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidine-3-one compounds as inhibitors of wee-1 kinase OA16752A|2015-12-14|armaceutical compositions. BR112021009988A2|2021-08-17|compound of formula |, or an n-oxide thereof, or a pharmaceutically acceptable salt, solvate, polymorph, tautomer, stereoisomer, an isotopic form, or a prodrug of said compound of formula | or n-oxide thereof , pharmaceutical composition, and method of treating a neoplastic disease WO2016149031A1|2016-09-22|Covalent inhibitors of cdk-7
同族专利:
公开号 | 公开日 CN103826630A|2014-05-28| WO2013040286A3|2013-05-10| NZ621386A|2015-05-29| NI201400022A|2014-04-23| AU2012308453B2|2016-11-10| AP2014007498A0|2014-03-31| EP3318284A1|2018-05-09| PT2758052T|2018-03-29| CO6930367A2|2014-04-28| ZA201401676B|2017-01-25| CA2847842C|2019-12-31| EP2758052B9|2019-03-27| ES2662775T3|2018-04-09| US9376395B2|2016-06-28| AP3656A|2016-04-04| PL2758052T3|2018-10-31| EP2758052A2|2014-07-30| CN103826630B|2016-12-07| RS57063B1|2018-06-29| JP2018039848A|2018-03-15| KR102048079B1|2019-11-22| CY1120080T1|2018-12-12| BR112014006271A2|2017-04-11| AU2012308453A1|2014-03-06| PE20141552A1|2014-11-08| TWI583382B|2017-05-21| JP2014526512A|2014-10-06| EP3318284B1|2022-01-26| HK1253692A1|2019-06-28| ME03088B|2019-01-20| IL230838D0|2014-03-31| CA2847842A1|2013-03-21| CR20140134A|2014-05-15| ECSP14013239A|2014-07-31| SI2758052T1|2018-05-31| KR20140078619A|2014-06-25| UA116333C2|2018-03-12| EA201490650A1|2014-06-30| WO2013040286A2|2013-03-21| EP2758052B1|2018-02-14| LT2758052T|2018-04-10| EP2758052A4|2015-05-27| CL2014000645A1|2014-10-03| HUE037575T2|2018-09-28| EA028413B1|2017-11-30| MX2014003283A|2014-05-21| AR087909A1|2014-04-23| HK1199824A1|2015-07-24| DK2758052T3|2018-05-28| IL230838A|2017-02-28| KR20190110148A|2019-09-27| JP6557318B2|2019-08-07| DOP2014000048A|2014-06-30| US20150183747A1|2015-07-02| GT201400069A|2015-07-13| MX346432B|2017-03-21| TN2014000095A1|2015-07-01| HRP20180690T1|2018-06-29| TW201316986A|2013-05-01| MY169495A|2019-04-15|
引用文献:
公开号 | 申请日 | 公开日 | 申请人 | 专利标题 US5376A|1847-11-20|Improvement in bog-cutters | US645A|1838-03-17|Back for poeges and fetrnages | DE34727C|Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue|Process for the direct extraction of metallic lead| US4522811A|1982-07-08|1985-06-11|Syntex Inc.|Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides| US6407079B1|1985-07-03|2002-06-18|Janssen Pharmaceutica N.V.|Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation| KR0166088B1|1990-01-23|1999-01-15|.|Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof| US5376645A|1990-01-23|1994-12-27|University Of Kansas|Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof| GB9126209D0|1991-12-10|1992-02-12|Orion Yhtymae Oy|Drug formulations for parenteral use| US5602112A|1992-06-19|1997-02-11|Supergen, Inc.|Pharmaceutical formulation| US5874418A|1997-05-05|1999-02-23|Cydex, Inc.|Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use| US6046177A|1997-05-05|2000-04-04|Cydex, Inc.|Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations| EP0986403B1|1997-06-13|2003-11-12|Cydex Inc.|Composition with extended shelf-life storage comprisingcyclodextrin and drugs or prodrugs that decompose to water-insoluble components| US7652036B2|2003-02-25|2010-01-26|Topotarget Uk Limited|Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors| CA2606598C|2005-05-13|2014-12-23|Topotarget Uk Limited|Pharmaceutical formulations of hdac inhibitors| CN101528215B|2006-10-20|2011-10-19|艾科斯有限公司|Compositions of chk1 inhibitors and cyclodextrin| WO2009100045A1|2008-02-04|2009-08-13|Translational Genomics Research Institute|Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives| MX2011002936A|2008-09-25|2011-04-11|Cephalon Inc|Liquid formulations of bendamustine.| ME02254B|2009-01-23|2015-12-31|Euro Celtique Sa|Hydroxamic acid derivatives| CN102421451B|2009-02-25|2013-11-06|休普拉特克药品有限公司|Bendamustine cyclopolysaccharide compositions| CN101928234B|2010-01-15|2012-12-12|北京欧凯纳斯科技有限公司|6/7-aryl-N-hydroxyl hexanamide/heptamide compounds and method for preparing same| JO3659B1|2010-06-02|2020-08-27|Astellas Deutschland Gmbh|Oral dosage forms of bendamustine and therapeutic use thereof| CN102993102B|2011-09-16|2016-08-24|杭州民生药业有限公司|The synthetic method of [1-methyl-2--5-N, N-bis-]-1H-benzimidazole|TWI573792B|2012-02-01|2017-03-11|歐陸斯迪公司|Novel therapeutic agents| CA2868302A1|2012-03-23|2013-09-26|Dennis M. Brown|Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo| WO2014070769A1|2012-10-29|2014-05-08|The University Of North Carolina At Chapel Hill|Methods and compositions for treating mucosal tissue disorders| GB201409488D0|2014-05-28|2014-07-09|Euro Celtique Sa|Pharmaceutical composition| GB201409471D0|2014-05-28|2014-07-09|Euro Celtique Sa|Pharmaceutical composition| GB201409485D0|2014-05-28|2014-07-09|Euro Celtique Sa|Pharmaceutical composition| EP3226903A1|2014-12-05|2017-10-11|University of Modena and Reggio Emila|Combinations of histone deacetylase inhibitors and bendamustine for use in the treatment of lymphoma| WO2017067474A1|2015-10-20|2017-04-27|杭州民生药物研究院有限公司|Pharmaceutical composition and preparation method therefor| US11266631B2|2016-10-11|2022-03-08|Purdue Pharmaceutical Products L.P.|Hodgkin lymphoma therapy| GB201709405D0|2017-06-13|2017-07-26|Euro-Celtique S A|Compounds for treating ovarian cancer| GB201709406D0|2017-06-13|2017-07-26|Euro-Cletique S A|Compounds for treating TNBC| GB201709403D0|2017-06-13|2017-07-26|Euro-Celtique S A|Compounds for treating sarcoma| JP6770986B2|2018-03-06|2020-10-21|日本電産モビリティ株式会社|Inductive load controller|
法律状态:
优先权:
[返回顶部]
申请号 | 申请日 | 专利标题 US201161536038P| true| 2011-09-18|2011-09-18| US201161536038P|2011-09-18| US201261602408P| true| 2012-02-23|2012-02-23| US201261602408P|2012-02-23| PCT/US2012/055277|WO2013040286A2|2011-09-18|2012-09-14|Pharmaceutical compositions| 相关专利
Sulfonates, polymers, resist compositions and patterning process
Washing machine
Washing machine
Device for fixture finishing and tension adjusting of membrane
Structure for Equipping Band in a Plane Cathode Ray Tube
Process for preparation of 7 alpha-carboxyl 9, 11-epoxy steroids and intermediates useful therein an
国家/地区
|